A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Andrei Iagaru, Giuseppe Cardaci, Aaron Richard Hansen, Jeffrey Y.C. Wong, Carlos Artigas, Karolien Goffin, Rafael Villanueva-Vázquez, Daniel Castellano, Felix Mottaghy, Anne Robert, Jing Zhao, Juan Zhang, Steffen Heeger, Karl Schumacher, Ken Herrmann

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5117

Source: Full article

---

Abstract

TPS5117